

COMPANY ANNOUNCEMENT

7th December 2023

No. 21-2023

ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19

MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Under the EU's Market Abuse Regulation article 19, ViroGates A/S must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on the trading of ViroGates shares.

ViroGates hereby notifies and submits the following transaction of shares in ViroGates: Jakob Knudsen, Chief executive officer of ViroGates A/S, bought subscription rights to shares in ViroGates on 5th and 6th December 2023. The subscription rights are related to the ongoing Rights emission in ViroGates.

The Form related to the transaction is attached.

The announcement can be found at https://www.virogates.com/announcements/.

For further information, please contact:

ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor.

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.



Skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres

1.	Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne			
a)	Navn	Jakob Knudsen		
2.	Årsag til indberetningen			
a)	Stilling/titel	Administrerende direktør		
b)	Første indberetning/æn- dring	Første indberetning		
3.	Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplat- formen, auktionsholderen eller den auktionstilsynsførende			
a)	Navn	ViroGates A/S		
b)	LEI-kode	5493007TX8XS56RMZD94		
4.	Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner			
a)	Beskrivelse af det finansielle instrument, instrumenttypen	Aktietegningsretter		
	Identifikationskode	DK0082814509		
b)	Transaktionens art	Køb		
c)	Pris(er) og mængde(r)	Pris(er)	Mængde(r)	
		1.869 DKK	8000	
		18.416 DKK	33000	
d)	Aggregerede oplysninger - Aggregeret mængde - Pris	41.000 Styk 20.285 DKK		
e)	Dato for transaktionen	05-06/12-2023		
f)	Sted for transaktionen	Nasdaq First North Growth Market Denmark (DSME)		